iScience · 2026
Multimodal parameters for the diagnosis of putative primaries of cancer of unknown primary.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pan Shuangyue, Wang Jinyan, Liu Jing, He Simin, Liu Xin, Zhang Xiaowei, Jiang Shiyu, Wang Yanli, Zhou Xiaoyan, Song Shaoli, Zhou Liangping, Li Haiming, Luo Jianfeng, Luo Zhiguo, Hu Silong, Wang Hongxia, Wang Qifeng, Hu Xichun
Аннотация
The Fudan cancer of unknown primary (CUP)-001 trial showed that the 90-gene assay-guided site-specific therapy (SST) can improve the survival of patients with CUP. A multidisciplinary team (MDT) for CUP explored whether multimodal parameters could improve the diagnosis of the putative primary site (PPS). The MDT adjudicated that 64 (49.2%), 22 (16.9%), 8 (6.2%), 14 (10.8%), and 4 (3.1%) patients had clues in pathology/immunohistochemistry (IHC), sentinel lymph nodes, Batson plexus, serum tumor marker patterns, and next-generation sequencing (NGS), respectively. The tumor marker was discarded because the PPS suggested by it had a less than 50% concordance rate with the PPS by the 90-gene assay or pathology/IHC. Only five patients (3.8%) had PPS diagnoses revised by the MDT. 113 (86.9%) patients were stageable as per the MDT, and the M1 stage was an independent prognostic factor for survival. In conclusion, the integration of the 90-gene assay with other multimodal parameters helps to establish a more reasonable, prognosis-related PPS diagnosis.